Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06500884 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

A Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 2
Development phase
130
Enrollment target
20
Study locations

NCT06500884: Recruiting Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma, sponsored by Janssen Research & Development.

NCT06500884 is a Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 130 participants, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06500884, a Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 2
Development phase
130 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.

Primary Outcome

Dysgeusia is defined as total WETT score of 25th percentile or below according to the Normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record

Conditions Studied

Refractory Multiple Myeloma Relapse Multiple Myeloma

Interventions

  • DRUG Talquetamab
  • DRUG Prophylaxis A
  • DRUG Prophylaxis B
  • DRUG Prophylaxis C

Study Locations (20)

Other

  • Hospitais Integrados da Gavea SA DF Star - Brasília
  • Fundacao Universidade de Caxias do Sul - Caxias do Sul
  • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer - Curitiba
  • Instituto D Or de Pesquisa e Ensino - Salvador
  • Clinica Medica Sao Germano S/S LTDA - São Paulo
  • Instituto D Or de Pesquisa e Ensino IDOR - São Paulo
  • VUMC Amsterdam - Amsterdam
  • Albert Schweitzer Ziekenhuis - Dordrecht
  • Erasmus MC - Rotterdam
  • Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center - San Juan
  • Seoul National University Hospital - Seoul

New York

  • Icahn School of Medicine at Mt. Sinai - New York
  • University of Rochester Medical Center - Rochester

California

  • University of California San Francisco - San Francisco

Colorado

  • Colorado Blood Cancer Institute - Denver

Connecticut

  • Yale University School Of Medicine - New Haven

North Carolina

  • Duke University Medical Center - Durham

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Virginia

  • Virginia Commonwealth University - Massey Cancer Center - Richmond

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2024-08-26
Est. Completion 2029-04-30
Phase Phase 2
Janssen Research & Development

593 total trials

What NCT06500884 shows while recruiting

NCT06500884 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher).

The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Talquetamab is the first listed.

NCT06500884 names 20 study sites across 9 states, led by Other, New York, California.

Frequently Asked Questions

What is clinical trial NCT06500884 about?

NCT06500884 is a clinical study titled "A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity". The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste...

What is the current status of trial NCT06500884?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2024-08-26. Estimated completion is 2029-04-30.

What conditions does trial NCT06500884 study?

This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma.

What interventions are being tested in trial NCT06500884?

The interventions under investigation include: Talquetamab (DRUG), Prophylaxis A (DRUG), Prophylaxis B (DRUG), Prophylaxis C (DRUG).

Who is sponsoring clinical trial NCT06500884?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06500884 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06500884's enrollment target sits among peer trials

130 3rd of 67 higher than 63 of 67 other Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06500884

Source: ClinicalTrials.gov NCT06500884, the US trial registry maintained by the National Library of Medicine. NCT06500884 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.